60¢sixtycents

Regeneron Pharmaceuticals, Inc.REGN

$609.94+2.01 (+0.33%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$66B
Large-cap
+61%
2016 — today
10-Year Price
+71%
2016 — today
52-Week Range
$511.92$812.27
Current $609.94· 33%

Regeneron Pharmaceuticals discovers, develops, and manufactures treatments for diverse medical conditions. Its portfolio includes EYLEA (ophthalmic conditions), Dupixent (atopic dermatitis, asthma), Libtayo (cancer), Praluent (cardiovascular), Kevzara (rheumatoid arthritis), Inmazeb (Ebola), ARCALYST (periodic syndromes), ZALTRAP (colorectal cancer), and REGEN-COV. It maintains extensive R&D collaborations with partners like Sanofi, Bayer, and Roche to address unmet needs in oncology, immunology, and rare diseases.

Valuation in context

P/E ratio
14.9
Historically cheap
Historically cheap relative to the last 10 years
P/B ratio
2.1
Near historic low
Near historic low — last 10 years
EV / EBITDA
11.4
Historically cheap
Historically cheap relative to the last 10 years
Dividend Yield
0.6%
Near historic high
Near historic highs — last 10 years
PEG ratio
4.9
Near historic high
Near historic highs — last 10 years
FCF Yield
6.3%
Historically high
Historically high relative to the last 10 years
Free · No credit card needed

Get alerted when REGN is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.